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OBJECTIVES: To investigate the prevalence of dyslipoproteinemia in a homogeneous cohort of polyarticular juvenile
idiopathic arthritis patients.
METHODS: Based on the National Cholesterol Education Program, fasting lipoprotein levels and risk levels for
coronary artery disease were determined in 28 patients with polyarticular juvenile idiopathic arthritis. The exclusion
criteria included diabetes, thyroid dysfunction, smoking, proteinuria, lipid-lowering drugs, and hormone/diuretic
therapy. Disease activity, disease duration, and therapy with corticosteroids and/or chloroquine were defined at the
time of lipid measurements.
RESULTS: Dyslipoproteinemia was identified in 20 of the 28 (71%) patients with polyarticular juvenile idiopathic
arthritis. The primary lipoprotein risk factor was decreased high-density lipoprotein cholesterol (57%), followed by
elevated levels of low-density lipoprotein cholesterol (18%), triglycerides (14%), and total cholesterol (7%). The
male patients had decreased high-density lipoprotein cholesterol levels than the female patients (p,0.05). The
incidence of decreased high-density lipoprotein cholesterol levels did not seem to be affected by disease activity or
therapy because the incidence was similar in patients with active or inactive disease, with or without corticosteroid
use and with or without chloroquine use. In addition, the frequency of decreased high-density lipoprotein
cholesterol levels was similar in patients with short (#5 years) vs. long (.5 years) disease duration.
CONCLUSIONS: Dyslipoproteinemia is highly prevalent in patients with polyarticular juvenile idiopathic arthritis and
is primarily related to decreased high-density lipoprotein cholesterol levels; therefore, early intervention is essential.
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INTRODUCTION
Overwhelming evidence indicates that abnormal lipopro-
tein levels play an important role in atherosclerotic processes
that can be related to autoimmune disease. Indeed, the risk to
develop atherosclerosis increases progressively with increas-
ing low-density lipoprotein cholesterol (LDL) levels and
declines with increasing levels of high-density lipoprotein
cholesterol (HDL).1 In adult patients with rheumatoid
arthritis (RA), coronary artery disease (CAD) is the leading
cause of shortened life expectancy relative to the general
population,2-4 and nearly half of these deaths can be attri-
buted to CAD that is linked to inflammation and elevated C-
reactive protein (CRP) levels.5,6 Another important factor that
certainly contributes to the development of atherosclerosis in
rheumatological diseases is abnormal lipid levels. Of note,
RA has its own pattern of dyslipoproteinemia (DL), and—
though they are controversial—most studies have demon-
strated decreased HDL levels in these patients.7,8
In juvenile idiopathic arthritis (JIA), the data regarding DL
prevalence are scarce and do not conclusively define the role
of JIA in this metabolic disturbance.9-14 One study found
altered lipid levels in both patients with active and inactive
JIA,9 whereas another study found that decreased HDL and
elevated triglyceride (TG) levels were strongly correlated with
the inflammatory state of the disease.12 These contradictory
findings may be explained by the broad spectrum of JIA
subtypes because specific clinical and laboratory parameters
can influence the lipid profile.15 Furthermore, an altered lipid
profile can occur in chronic inflammatory states that favor
atherosclerosis.16 Therefore, we evaluated the prevalence of
DL in a homogeneous group of polyarticular JIA patients to
define CAD lipoprotein risk in this patient population.
METHODS
Study population: One hundred and eighty JIA patients
who were regularly followed at the Rheumatology Division
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of Hospital das Clı´nicas da Universidade de Sa˜o Paulo were
initially evaluated for this study. All of the patients fulfilled
the International League of Associations for Rheumatology
(ILAR) criteria for JIA.17 Forty JIA patients were eligible for
this study after excluding patients with diabetes mellitus,
hypertension, renal disease, infection, thyroid or hepatic
dysfunction, pregnancy, smoking, or the intake of drugs
that could interfere with lipid metabolism (such as
hormones, lipid-lowering agents, diuretics, and prednisone
.10 mg/day). We then excluded JIA patients with systemic
or oligoarticular JIA, enthesopathy-related arthritis (ERA),
psoriatic arthritis, and inflammatory bowel disease to define
a homogeneous group of 28 patients with polyarticular
onset JIA. Corticosteroid and diphosphate chloroquine
intake was calculated for each patient by analyzing the
mean dosage over the previous three months and the stable
dosage at least one month prior to inclusion in this study.
The local ethics committee approved this study, and
written, informed consent was obtained from each patient.
JIA disease activity: Clinical JIA disease activity was
defined as the presence of clinically active synovitis in at least
one joint together with an elevated erythrocyte sedimentation
rate (ESR) (with normal defined as ,12 mm/h) and/or
elevated CRP levels (with normal defined as ,5 mg/dl].
Biochemical analysis
Plasma lipid levels: Each subject followed their own
regular diet, and blood samples for lipoprotein evaluation
were obtained after a 12-h overnight fast. Plasma total
cholesterol (TC) and TG levels were measured enzymati-
cally (Boehringer Mannheim, Buenos Aires, Argentina and
Merck, Darmstadt, Germany, respectively) using an RA
1000 analyzer (Technicon Instruments Corp., Tarrytown,
NY, USA).18,19 HDL levels were obtained after precipitating
very low-density lipoprotein cholesterol (VLDL) and LDL
with phosphotungstic acid and magnesium chloride.20
VLDL and LDL levels were estimated for samples with
TG levels that were lower than 400 mg/dl.21 VLDL levels
were calculated by multiplying the TG level by 0.45, and
LDL levels were estimated using the following equation:
LDL = TC – (HDL+TG)/5.21
Lipoprotein risk levels for CAD: Lipoprotein risk levels
for the JIA patients were determined based on the updated
recommendations from the Brazilian consent guidelines for
the detection and treatment of DL, which were established by
the Brazilian Society of Cardiology and the Brazilian Society
of Pediatrics.22 These guidelines are in accordance with the
National Cholesterol Education Program (NCEP) for subjects
who are older than 20 years of age23 and for children and
adolescents (NCEP-Peds) ranging from 2 to 19 years of age.24
Statistical analysis: Values are expressed as the mean¡
standard deviation (SD). Statistical comparisons were
performed using the Mann-Whitney test, Kruskal-Wallis
test, Student’s t-test or x2 test (Pearson Chi-square or
Fisher’s exact test), as appropriate. The relative risks for DL
according to chloroquine and steroid intake and disease
activity and duration were calculated by estimating the
odds ratio (OR) and 95% confidence interval (95% CI) using
unconditional binary logistic regression. Differences with a
p-value ,0.05 were considered to be significant. All of the
analyses were performed using the Statistical Package of
Social Sciences, version 15.0 for Windows (SPSS Inc.,
Chicago, IL, USA).
RESULTS
We found a clear female predominance (75%) among the
28 polyarticular onset JIA patients. The mean age of all 28
patients was 19.9¡5.8 years, with 11 (39%) patients younger
than 20 years and 17 (61%) patients older than 20 years. The
mean weight and body mass index were 54¡10.2 kg and
21¡3.9 kg/m2, respectively.
The mean disease duration was 9.4¡5.4 years. Upon joining
the study, 17 of the patients (60.7%) had active JIA with a mean
of four active joints (range 1-10 joints) and mean ESR and CRP
levels of 26.4¡27.0 mm/h (range 1-110 mm/h) and
15.5¡23.2 mg/dl (range 0.26-76.9 mg/dl), respectively. At
the time of their evaluation, 16 (57.1%) patients were taking
diphosphate chloroquine at a mean dose of 227.2¡56 mg/
day, range 50-250 mg/day (4 mg/kg/day), and nine (32.1%)
patients were taking a low dose of prednisone with a mean
dose of 5.8¡2.5 mg/day, range 2.5-10 mg/day (0.1 mg/kg/
day). Additionally, 12 (42.8%) of the patients were on
immunosuppressive therapy as follows: methotrexate at
18.7¡7.1 mg/day, range 10-30 mg/day (0.4 mg/kg/day),
sulfasalazine at 2.2¡0.6mg/day, range 1.5-3.0 mg/day
(0.04 mg/kg/day) and azathioprine at 75¡35.3 mg/day,
range 50-100 mg/day (1.2 mg/kg/day). None of the patients
were receiving biological therapy. All of the patients had a
serum creatinine level below 1.3 mg/dl and a proteinuria level
of less than 0.3 g (0.05¡0.01 g/24 h).
As shown in Table 1, the lipoprotein levels revealed a mean
TC level of 150.3¡26.0 mg/dl, LDL level of 83.6¡23.1
mg/dl, HDL level of 50.6¡11.6 mg/dl, and TG level of
81.6¡49.4 mg/dl. According to the normal lipoprotein levels
adjusted for the age range,23,24 57% of the subjects (16/28) had
decreased HDL levels. In contrast, abnormal TC, LDL, and TG
levels were observed in only 7 (2/28), 18 (5/28), and 14%
(4/28) of the patients, respectively. Remarkably, the male
patients had lower HDL levels than the female patients
(42.6¡12.6 mg/dl vs. 53.3¡10.1 mg/dl, respectively; p,0.05)
(Table 1).
Decreased HDL levels were not associated with disease
activity (p = 0.07), corticosteroid (p= 1.0), or chloroquine
therapy (p = 0.4). The frequency of patients with decreased
HDL was similar in patients with a short (#5 years) or long
(.5 years) disease duration (50% vs. 50%, respectively;
p = 1.0). A trend towards increased LDL levels was observed
for the patients who were taking corticosteroid (OR: 9.0,
95% CI: 0.8 to 103.7, p = 0.05) but not for the patients were
taking chloroquine or who had active JIA (p.0.05).
Moreover, neither disease activity nor therapy influenced
either the TC or TG levels (p.0.05).
An evaluation of the stratified lipoprotein risk factors for
CAD revealed that 71% (20/28) of the patients had risk
factors, with sixteen patients having one factor and four
patients having two or more. Among the sixteen patients
with a single lipoprotein risk factor, 81% (13/16) were
attributed to decreased HDL levels.
DISCUSSION
In this study, we found decreased HDL levels in
polyarticular onset JIA patients, and this finding was not
related to disease activity, disease duration, or therapy.
Furthermore, we demonstrate here for the first time that
male patients with polyarticular onset JIA have significantly
lower HDL levels than female patients.
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In contrast to previous studies, the lipid profile that we
evaluated was focused on a homogeneous population of JIA
patients with polyarticular onset.
JIA encompasses a broad spectrum of diseases, and a
systemic onset has a pattern of inflammatory markers—with
oligoarticular and polyarticular JIA subtypes having distinct
markers—that can influence abnormal lipid levels.15
In this respect, there are differing reports of abnormal
lipoprotein levels in JIA patients and a lack of a definitive
prevalence of DL for this disease.9-14 Ilowite and colleagues9
were the first to describe an altered lipoprotein profile in both
active and inactive JIA patients that was characterized by
decreased HDL levels and increased TG and VLDL levels.
Interestingly, these abnormalities were primarily observed in
those patients with an active, systemic subtype of the disease.9
In addition, an elevated TG level was the only finding that was
observed in 99 Polish children with JIA (compared to age-
matched healthy controls) when several subtypes of the
disease were evaluated.10 In contrast, no significant differences
in TG, HDL, TC, or apolipoprotein B levels were detected
between 37 Turkish JIA patients and 18 controls, although an
inverse correlation between apolipoprotein A1 and inflamma-
tory markers (ESR and CRP) was observed.11 However, a
study of 26 Greek children with JIA found decreased HDL and
elevated TG levels that were strongly correlated with the
inflammatory state of the disease.12 Overall, ethnic differences,
lifestyle, and environmental factors as well as genetic back-
ground may help explain these varied observations that are
related to DL in patients with juvenile arthritis.25,26
Our results are in agreement with the majority of previous
studies that have shown decreased HDL levels in patients
with JIA. Decreased HDL levels have been described in
patients with systemic lupus erythematosus (SLE); indeed,
our group has previously reported decreased HDL levels in
88% of patients with juvenile SLE and a trend for an
association of this reduced level with the active disease.30
In contrast to some studies that have demonstrated a
correlation with active disease,9,11,12 we found no association
between decreased HDL cholesterol levels and disease
activity; in this regard, abnormal lipid levels in active JIA
may be related to the inflammatory state of the disease.9,11,12
Considering the 15% probability of achieving disease
remission within ten years of the initial diagnosis of
polyarticular JIA,31 most children will enter adulthood with
ongoing active arthritis. In fact, more than 30% of our JIA
patients still had active JIA five years after onset; thus, chronic
inflammation seems to be a relevant issue of concern.
Although the relationship between physical activity and
HDL was not addressed in this study, we can speculate that
persistent active disease associated with physical incapacity
due to functional impairment may play an important role in
the dyslipidemic status that we observed in our JIA patients
because a sedentary lifestyle is a contributing factor for
decreased HDL. Moreover, decreased physical activity was
recently associated with proinflammatory HDL in patients
with SLE, which suggests that exercise can modulate the
development of cardiovascular disease in this group of
patients, possibly by decreasing inflammatory mediators.32
Alternatively, the role of drug intake may be a component
of the abnormal lipid levels that we observed. Our findings
cannot be explained by chloroquine treatment, which has a
lipid-lowering effect that promotes an increase in HDL
levels.33 Moreover, decreased HDL levels cannot be related to
steroid use, which enhances the levels of all lipid fractions.34
Furthermore, although diet intake was not specifically
investigated, the majority of the children that we evaluated
had a normal BMI, and we excluded children with diabetes
or other factors that could have interfered with our
evaluation of lipoprotein levels and CAD risk stratification.
In conclusion, we found a elevated prevalence of altered
lipoprotein profiles in polyarticular onset JIA that was
primarily related to decreased HDL levels and male gender,
thereby emphasizing the need for early intervention in
order to minimize this perturbation. Additional studies are
needed to determine the role of diet, statins, and exercise in
preventing cardiac events in JIA patients, with the aim of
effectively assessing whether physical fitness and drug
intake will have beneficial effects on future cardiovascular
disease in these patients.
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Table 1 - Characteristics and lipid profiles of 28 patients with polyarticular JIA.
Variable JIA patients (n = 28)
Female gender
(n= 21)
Male gender
(n= 7) p-value{
Age, years 19.86¡5.79
(5-29)
20.00¡5.64 19.43¡6.68 0.826
Age at diagnosis, years 10.00¡5.03
(1-16)
9.62¡4.96 11.14¡5.43 0.498
Disease duration, years 9.36¡5.41
(1-25)
9.71¡5.12 8.29¡6.52 0.555
Total cholesterol, mg/dl 150.29¡26.04
(104-206)
150.71¡26.44 149.00¡26.78 0.883
Triglycerides, mg/dl 81.61¡49.36
(33-255)
72.62¡35.00 108.57¡75.82 0.265
HDL, mg/dl 50.61¡11.55
(30-74)
53.29¡10.11 42.57¡12.62 0.031
LDL, mg/dl 83.61¡23.06
(41-138)
83.29¡22.49 84.57¡26.58 0.901
CV risk factor, number 0.96¡0.92
(0-4)
0.90¡0.89 1.14¡1.07 0.640
Except where indicated otherwise, data are expressed as mean¡standard deviation; the values in parentheses indicate the range. LDL – decreased-density
lipoprotein cholesterol; HDL – high-density lipoprotein cholesterol; CV – cardiovascular. {p-values represent the correlation between female and male
patients. The p-value in bold is statistically significant.
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